Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international,... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Lancet. Oncology Pubmed

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

Loading next page...
 
/lp/pubmed/lorlatinib-in-non-small-cell-lung-cancer-with-alk-or-ros1-o7gBktHutJ

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

DOI
10.1016/S1470-2045(17)30680-0
pmid
29074098

Abstract

Journal

The Lancet. OncologyPubmed

Published: Dec 15, 2017

There are no references for this article.